Centene Corporation
CNC
$64.99
+0.59%
Centene Corporation is a managed care organization that specializes in government-sponsored healthcare programs, operating Medicaid, Medicare, and individual exchange plans across the United States, and serving approximately 20 million medical members as of December 2025. The company is a dominant player in the Medicaid managed care space, with roughly 64% of its membership in Medicaid, 28% in individual exchanges, and 5% in Medicare, positioning it as a pure-play on government-funded healthcare rather than a diversified commercial insurer. The current investor narrative is centered on a dramatic earnings recovery and margin turnaround following a severe 2025 downturn, with the stock up over 71% in the past year as cost trends stabilize and guidance is raised. However, recent headlines highlight a membership slump in Affordable Care Act plans that has forced the company into voluntary staff buyouts, signaling near-term revenue pressure even as management pivots toward profitability. The debate among investors is whether Centene's margin recovery is sustainable amid Medicaid redetermination headwinds and exchange membership attrition, or whether the recent rally has already priced in the turnaround.…
CNC
Centene Corporation
$64.99
Related headlines
Investment Opinion: Should I buy CNC Today?
Based on the synthesis of data, Centene warrants a Buy rating for investors with a moderate risk tolerance and a long-term horizon. The core thesis is that the company is in the midst of a dramatic earnings recovery, trading at a deep discount to peers and its own history, with analyst consensus targeting 13.9% upside. The average target price of $71.78 and the buy consensus (mean 2.38) support a constructive view, though the recent pullback and membership headwinds suggest near-term caution.
The supporting evidence is compelling: forward PE of 11.78 is 30-40% below the managed care industry average, revenue is expected to stabilize with estimated average revenue of $209.4 billion, and profitability has swung from a Q2 2025 loss of $253 million to Q2 2026 net income of $1.091 billion. Free cash flow is robust at $8.968 billion TTM, and the company holds $24.254 billion in cash. The PS ratio of 0.104 is near historic lows, and price-to-book of 1.01 is at the low end of its five-year range, suggesting the market is undervaluing the recovery.
However, risks could invalidate the thesis: continued ACA membership losses, margin volatility (gross margin fell to 10.4% in Q2 2026 from 21.9% in Q1), and leverage (debt-to-equity 0.941). The rating would upgrade to a strong buy if membership stabilizes and gross margin holds above 15%, or downgrade to Hold if revenue declines accelerate beyond 10% year-over-year. Relative to history and peers, Centene appears undervalued, but the market is pricing in skepticism about the sustainability of the turnaround.
Sign up to view all
CNC 12-Month Price Forecast
The forward-looking view is balanced but leans cautiously optimistic. Centene's earnings recovery is impressive, and the valuation is undemanding, but revenue contraction and membership losses are significant headwinds. The analyst consensus targets moderate upside, yet the wide target range reflects uncertainty. I would upgrade to bullish if the company demonstrates two consecutive quarters of membership stabilization and gross margin above 12%. Conversely, a downgrade to bearish would occur if revenue declines accelerate beyond 10% or if medical cost trends worsen, compressing margins further. The risk/reward is skewed positively for long-term investors, but near-term volatility is likely.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Centene Corporation's 12-month outlook, with a consensus price target around $71.78 and implied upside of +10.4% versus the current price.
Average Target
$71.78
0 analysts
Implied Upside
+10.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$56 - $85
Analyst target range
Centene is covered by 18 analysts, with a consensus recommendation of "buy" and a recommendation mean of 2.38 on a scale where 1 is a strong buy and 5 is a strong sell. The average target price is $71.78, which implies approximately 13.9% upside from the current price of $62.99, calculated as ($71.78 - $62.99) / $62.99. The consensus leans moderately bullish, with the buy rating supported by the company's earnings recovery and raised guidance, though the recommendation mean of 2.38 suggests a mix of buy and hold ratings rather than overwhelming conviction. Recent institutional ratings show a predominantly constructive tone, with Argus Research upgrading from Hold to Buy on August 11, 2026, and firms like Bernstein, Barclays, and Cantor Fitzgerald maintaining Outperform or Overweight ratings.\n\nThe target price range spans from a low of $56.00 to a high of $85.00, representing a spread of $29.00, or approximately 51.8% of the low target, which signals meaningful uncertainty about the company's trajectory. The high target of $85.00 implies roughly 34.9% upside from the current price and assumes successful execution on margin expansion, sustained earnings recovery, and potentially multiple expansion as the market gains confidence in the turnaround. The low target of $56.00 implies approximately 11.1% downside from the current price and likely prices in continued membership attrition in the exchange segment, potential margin compression from elevated medical cost trends, or a broader sector de-rating. The wide spread between the high and low targets reflects the binary nature of the investment case, where the outcome depends heavily on whether Centene can stabilize membership and maintain its improved margin profile. The estimated EPS average of $9.84 for the forward year, with a range of $9.418 to $10.172, provides a relatively tight earnings forecast band, suggesting analysts have reasonable confidence in the near-term earnings trajectory even if they disagree on the appropriate multiple.
Bulls vs Bears: CNC Investment Factors
The bull case rests on a powerful earnings recovery, deep valuation discount, and strong cash flow, while the bear case highlights revenue contraction, margin volatility, and recent negative momentum. Currently, the bull evidence appears stronger given the dramatic swing to profitability, robust free cash flow, and analyst consensus for upside, but the bear points are not trivial—membership losses and margin inconsistency pose real threats. The single most important tension is whether Centene can stabilize its individual exchange membership and maintain improved medical cost trends; if it can, the stock is significantly undervalued, but if membership attrition continues, the recovery could stall. The recent pullback from the 52-week high may present an entry opportunity for long-term investors, but near-term volatility is likely to persist.
Bullish
- Earnings recovery is dramatic and accelerating: Q2 2026 net income swung to $1.091 billion from a $253 million loss in Q2 2025, a $1.34 billion improvement. Q1 2026 net income was even stronger at $1.541 billion, and the forward EPS estimate of $9.84 implies a massive turnaround from trailing EPS of -$0.33.
- Deep valuation discount to peers and history: The forward PE of 11.78 is 30-40% below the managed care industry average of 15-20x, while the PS ratio of 0.104 sits far below the historical range of 0.32 to 1.48. Price-to-book of 1.01 is near the low end of its five-year range (0.75-1.91), suggesting the market is not pricing in the recovery.
- Strong free cash flow and liquidity: Trailing twelve-month free cash flow is $8.968 billion, with Q2 2026 alone generating $4.199 billion. Cash on hand rose to $24.254 billion at the end of Q2 2026 from $20.587 billion in Q1, providing ample liquidity to manage membership transitions and fund operations.
- Analyst consensus sees 13.9% upside: The average analyst target price of $71.78 implies 13.9% upside from the current $62.99, with a consensus recommendation of 'buy' (mean 2.38). Argus Research upgraded to Buy on August 11, 2026, and the high target of $85 implies 34.9% upside.
Bearish
- Revenue contraction and membership losses: Q2 2026 revenue declined 8.96% year-over-year to $44.375 billion, and sequentially fell 11.1% from Q1 2026. The ACA membership slump has forced voluntary staff buyouts, signaling structural pressure in the individual exchange segment, which represents 28% of membership.
- Margin volatility and trailing losses: Q2 2026 gross margin of 10.4% remains well below Q1 2026's 21.9%, highlighting quarter-to-quarter volatility in medical cost trends. The trailing twelve-month net margin is -3.43% and operating margin is -3.91%, reflecting the catastrophic Q3 2025 loss of $6.631 billion.
- Recent momentum has turned negative: The stock is down 6.46% over the past month and 7.18% over the past three months, underperforming the S&P 500 by 7.05% and 10.52%, respectively. This divergence from the strong 1-year gain of 71.08% suggests profit-taking and potential mean reversion.
- Leverage and negative ROE: Debt-to-equity stands at 0.941, and the cash flow to debt ratio of 0.272 indicates a meaningful debt burden. Return on equity is -33.44% on a trailing basis, reflecting the impact of prior losses and raising questions about capital efficiency.
CNC Technical Analysis
Centene is in a powerful recovery uptrend, with the stock up 71.08% over the past year and 50.77% year-to-date, a dramatic reversal from the deep losses of 2025. The current price of $62.99 sits at approximately 90.4% of the 52-week range, calculated as ($62.99 - $31.63) / ($69.63 - $31.63), placing it near the upper end of its annual trading band. This positioning signals strong momentum but also raises the risk of overextension, especially given the stock's 32.73% maximum drawdown over the past year, which underscores the volatility of its recovery path. The 52-week high of $69.63 was set in mid-September 2026, and the stock has since pulled back about 9.5% from that peak, suggesting a potential consolidation phase.\n\nShort-term momentum has turned negative and is diverging sharply from the longer-term uptrend. The stock is down 6.46% over the past month and 7.18% over the past three months, while the S&P 500 gained 0.59% and 3.34% over the same periods, resulting in relative strength of -7.05% and -10.52%, respectively. This divergence between the strong 1-year gain (+71.08%) and the recent 1-month and 3-month declines suggests a mean-reversion pullback or profit-taking after a substantial run, rather than a full trend reversal, given the stock remains well above its 52-week low. The 6-month change of +79.41% and relative strength of +62.06% versus SPY confirm that the bulk of the rally occurred in the first half of 2026, with momentum decelerating in recent months.\n\nKey technical support is anchored at the 52-week low of $31.63, with intermediate support likely around the $55-$58 zone where the stock consolidated in May and June 2026. Resistance is defined by the 52-week high of $69.63, and a breakout above this level would signal renewed bullish conviction and potentially open the door to the analyst high target of $85. Conversely, a breakdown below the $55 support area would suggest the recovery trade is losing steam and could expose the stock to a retest of lower levels. The stock's beta of 1.106 indicates it is approximately 10.6% more volatile than the broader market, which is relatively moderate for a managed care organization but still warrants careful position sizing given the stock's recent 32.73% maximum drawdown.
Beta
1.13
1.13x market volatility
Max Drawdown
-32.7%
Largest decline past year
52-Week Range
$32-$70
Price range past year
Annual Return
+69.2%
Cumulative gain past year
| Period | CNC Return | S&P 500 |
|---|---|---|
| 1m | -3.1% | +0.9% |
| 3m | -3.9% | +3.4% |
| 6m | +74.2% | +14.4% |
| 1y | +69.2% | +16.2% |
| ytd | +55.6% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CNC Fundamental Analysis
Centene's revenue trajectory shows signs of contraction, with Q2 2026 revenue of $44.375 billion representing a -8.96% year-over-year decline from Q2 2025's $48.742 billion. This decline is primarily driven by membership losses in the individual exchange segment, as highlighted by recent reports of a significant ACA membership slump. On a sequential basis, revenue fell from $49.944 billion in Q1 2026 to $44.375 billion in Q2 2026, a 11.1% quarter-over-quarter decline, reflecting both seasonal factors and structural membership attrition. The revenue segment breakdown shows Medicaid as the largest contributor at $31.97 billion, followed by Medicare at $11.057 billion, Commercial at $9.356 billion, and Other at $1.196 billion, with the exchange membership decline posing a direct threat to the Commercial segment's contribution.\n\nProfitability has improved dramatically from the losses of 2025, with Q2 2026 net income of $1.091 billion compared to a net loss of $253 million in Q2 2025, a swing of over $1.3 billion. The Q2 2026 gross margin of 10.4% is an improvement from the 6.0% gross margin in Q2 2025 but remains below the 21.9% gross margin reported in Q1 2026, indicating some quarter-to-quarter volatility in medical cost trends. The trailing twelve-month net margin is -3.43%, reflecting the drag from the catastrophic Q3 2025 loss of $6.631 billion, but the forward-looking picture is brighter with Q1 2026 net income of $1.541 billion and Q2 2026 net income of $1.091 billion suggesting a return to sustained profitability. The operating margin of -3.91% on a trailing basis contrasts with the Q2 2026 operating income of $1.375 billion, or a 3.1% operating margin, showing the company is back in the black on an operating basis.\n\nThe balance sheet presents a mixed picture, with a debt-to-equity ratio of 0.941 and a current ratio of 1.676, indicating adequate liquidity but meaningful leverage. Free cash flow on a trailing twelve-month basis is robust at $8.968 billion, and Q2 2026 alone generated $4.199 billion in free cash flow from $4.373 billion in operating cash flow, demonstrating strong cash generation capability. The company holds $24.254 billion in cash at the end of Q2 2026, up from $20.587 billion at the end of Q1 2026, providing substantial liquidity to fund operations and manage the membership transition. However, the return on equity of -33.44% reflects the trailing losses, and the cash flow to debt ratio of 0.272 from historical ratios suggests that while cash generation is strong, the debt burden remains a consideration for financial risk assessment.
Quarterly Revenue
$44.4B
2026-06
Revenue YoY Growth
-9.0%
YoY Comparison
Gross Margin
10.4%
Latest Quarter
Free Cash Flow
$9.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CNC Overvalued?
Because Centene reported negative trailing net income (EPS of -$0.33), the trailing PE ratio of -3.02 is not meaningful, and the PS ratio is the appropriate primary metric for valuation analysis. The current PS ratio is 0.104, which is exceptionally low on an absolute basis, while the forward PE of 11.78 based on estimated EPS of $9.84 provides a more constructive view of valuation once the earnings recovery is factored in. The gap between the negative trailing PE and the positive forward PE of 11.78 implies that the market is pricing in a substantial earnings recovery, with analysts projecting EPS to swing from -$0.33 to $9.84, a dramatic turnaround that justifies the recent stock price appreciation.\n\nComparing Centene's valuation to the broader healthcare sector, the forward PE of 11.78 is significantly below the industry average for managed care organizations, which typically trade in the 15-20x range, representing a discount of approximately 30-40%. The PS ratio of 0.104 is also remarkably low, though this is partly a function of Centene's high-revenue, low-margin business model typical of managed care. The EV/Sales ratio of 0.107 and EV/EBITDA of -4.10 (negative due to trailing EBITDA losses) further illustrate the depressed valuation on trailing metrics, while the forward-looking earnings estimates suggest the stock is trading at a discount to peers on normalized earnings power. The PEG ratio of 0.0096 is extremely low, though this metric is distorted by the negative trailing earnings base and should be interpreted with caution.\n\nHistorically, Centene's PS ratio has ranged from a low of 0.32 in Q1 2026 to a high of 1.48 in Q4 2021, with the current PS of 0.104 sitting well below the historical range, suggesting the stock is trading at a deep discount to its own history. The historical PE ratio has been highly volatile, ranging from -4.59 in Q4 2025 to 220.34 in Q4 2023, reflecting the cyclicality of the managed care business and the impact of medical cost trends. The current price-to-book ratio of 1.013 is near the lower end of the historical range (which has ranged from 0.75 to 1.91 over the past five years), indicating that the market is not assigning a premium to Centene's book value despite the earnings recovery. This historical context suggests that either the market is skeptical of the sustainability of the recovery, or the stock remains undervalued relative to its long-term valuation bands.
PE
-3.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-4.1x
Enterprise Value Multiple
Investment Risk Disclosure
Centene faces significant financial and operational risks. The company's revenue declined 8.96% year-over-year in Q2 2026 to $44.375 billion, driven by ACA membership losses, and sequential revenue fell 11.1% from Q1 2026. Gross margin is volatile, dropping to 10.4% in Q2 2026 from 21.9% in Q1 2026, indicating sensitivity to medical cost trends. With a debt-to-equity ratio of 0.941 and a cash flow to debt ratio of 0.272, the balance sheet carries meaningful leverage, and the trailing ROE of -33.44% reflects the drag from the Q3 2025 loss of $6.631 billion. Additionally, the company's membership concentration—64% Medicaid and 28% exchanges—exposes it to regulatory and funding changes in government-sponsored healthcare.
Market and competitive risks are also prominent. Centene trades at a forward PE of 11.78, which is a discount to peers, but if the earnings recovery falters, the multiple could compress further. The stock's beta of 1.106 indicates it is 10.6% more volatile than the market, and its recent 32.73% maximum drawdown underscores the potential for sharp declines. The ACA membership slump has forced staff buyouts, highlighting competitive pressures and potential market share erosion. Regulatory headwinds, such as changes to Medicaid redetermination or Medicare Advantage payment rates, could adversely affect revenue and margins. The recent CMS boost to 2027 Medicare payments is a positive, but it may not fully offset exchange segment weakness.
In a worst-case scenario, continued membership attrition and margin compression could drive the stock back toward its 52-week low of $31.63, representing a 49.8% decline from the current price of $62.99. The analyst low target of $56 implies an 11.1% downside, but a more severe outcome could see the stock retest the $31.63 level if the earnings recovery reverses. This would equate to a loss of approximately 50% from current levels. Such a scenario would likely involve a combination of regulatory changes, worsening medical cost trends, and failure to stabilize exchange membership, leading to further earnings misses and multiple contraction.
FAQ
The key risks include: 1) Membership attrition in ACA exchanges, which contributed to an 8.96% YoY revenue decline in Q2 2026 and forced staff buyouts; 2) Margin volatility, with gross margin dropping to 10.4% in Q2 2026 from 21.9% in Q1, highlighting sensitivity to medical costs; 3) Regulatory risk, as 64% of membership is in Medicaid, exposing the company to changes in government funding and redetermination policies; 4) Leverage, with debt-to-equity of 0.941 and a cash flow to debt ratio of 0.272, which could constrain financial flexibility if earnings disappoint. These risks are ranked from most to least severe, with membership attrition being the most immediate threat.
The 12-month forecast includes three scenarios: bull case (30% probability) targeting $75-$85, base case (50%) targeting $65-$75, and bear case (20%) targeting $45-$56. The base case is most likely, assuming EPS of $9.84 and revenue around $209.4 billion, with the stock trading near the analyst average target of $71.78. The bull case requires successful membership stabilization and margin expansion, while the bear case involves continued attrition and margin compression. The key assumption behind the base case is that Centene meets analyst expectations without major regulatory disruptions.
CNC appears undervalued on both absolute and relative bases. The PS ratio of 0.104 is far below its historical range of 0.32 to 1.48, and the forward PE of 11.78 is significantly below the managed care industry average of 15-20x. Price-to-book of 1.01 is near the low end of its five-year range (0.75-1.91). The market is pricing in skepticism about the sustainability of the earnings recovery, as evidenced by the negative trailing PE of -3.02. If the company meets forward EPS estimates of $9.84, the stock could re-rate higher. However, the low valuation also reflects genuine risks, including revenue contraction and margin volatility.
From a risk/reward perspective, CNC appears attractive for value investors. The stock trades at a forward PE of 11.78, a 30-40% discount to peers, with analyst consensus targeting 13.9% upside to $71.78. The earnings recovery is robust, with Q2 2026 net income of $1.091 billion versus a loss a year ago, and free cash flow is strong at $8.968 billion TTM. However, the biggest downside risk is continued ACA membership losses, which could push the stock toward the analyst low target of $56 (11.1% downside) or worse. It is a good buy for investors with a long-term horizon who can tolerate volatility, but near-term headwinds may cap gains.
CNC is more suitable for long-term investment (minimum 2-3 years) given its turnaround nature and the time needed for membership stabilization and margin recovery. The stock's beta of 1.106 indicates moderate volatility, and the 32.73% maximum drawdown over the past year highlights the potential for sharp swings. The company pays no dividend, so returns depend entirely on capital appreciation. Short-term trading is risky due to earnings volatility and regulatory headlines. A long-term horizon allows investors to capture the potential re-rating as the earnings recovery materializes and the valuation normalizes toward peer levels.